Nexlizet is a combination of 2 medicines, bempedoic acid and ezetimibe. The bempedoic acid portion of nexlizet was studied in a large clinical trial on reducing heart attack and heart procedures, like … Bempedoic acid, a component of nexlizet, is used:

Bempedoic acid, a component of nexlizet, is indicated: €¢ to reduce the risk of major adverse cardiovascular events (cardiovascular death, myocardial infarction, stroke, or coronary … Nexlizet is indicated as an adjunct therapy to diet and maximally-tolerated statin therapy. Nexlizet is a combination treatment of two drugs, bempedoic acid and ezetimibe. Bempedoic acid is a member of … The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of nexlizet and nexletol, at an incidence of ≥2% and 0. 5% greater than placebo …

Bempedoic acid is a member of … The most common adverse reactions in the cardiovascular outcomes trial for bempedoic acid, a component of nexlizet and nexletol, at an incidence of ≥2% and 0. 5% greater than placebo …